ZT 01
Alternative Names: ZT-01Latest Information Update: 28 Aug 2024
At a glance
- Originator Tulane University; University of Toronto; York University
- Developer Zucara Therapeutics
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Somatostatin receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypoglycaemia
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Hypoglycaemia in Canada (SC, Injection)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Hypoglycaemia(Prevention) in Canada (Intraperitoneal)
- 21 Jun 2024 pharmacodynamics data from preclinical studies in Hypoglycaemia presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)